^
    3d
    A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Datroway (datopotamab deruxtecan-dlnk) • Yidafan (ivonescimab)
    3d
    InCITe: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=145, Active, not recruiting, Laura Huppert, MD, BA | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    4d
    Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis. (PubMed, Breast Cancer Res Treat)
    SG-induced SN and FN rates were similar to those reported in clinical trials, both in the HR + /HER- mBC and mTNBC groups. Due to small sample size, we did not identify any statistically significant risk factors of SG-associated SN. Our study provided insights into G-CSF use patterns and costs in real-world SG therapy.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy)
    4d
    A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care (clinicaltrials.gov)
    P3, N=364, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P3 trial
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    4d
    Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. (PubMed, J Clin Pharmacol)
    Exposure-safety analysis further supported that this approach may reduce the potential associated safety risks. These results support the recommended Dato-DXd dosing regimen (6 mg/kg Q3W with dose capping for patients ≥90 kg) and highlight its favorable benefit-risk profile in patients with HR+/HER2-breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Datroway (datopotamab deruxtecan-dlnk)
    5d
    TROPION-Lung17: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=400, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    docetaxel • Datroway (datopotamab deruxtecan-dlnk)
    6d
    Oncologic strategies and options for the management of metastatic thymic carcinoma. (PubMed, Mediastinum)
    Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.
    Review • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin)
    |
    KIT mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • bintrafusp alfa (M7824) • Yidafan (ivonescimab)
    6d
    PROTECT-2: Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=49, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Dec 2027 | Initiation date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Mar 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    EGFR mutation
    |
    Cosela (trilaciclib) • Jiataile (sacituzumab tirumotecan)
    7d
    Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. (PubMed, Antib Ther)
    Comparative studies with a surrogate of sacituzumab govitecan were performed in TROP2-expressing tumor models...Novel anti-TROP2 ADCs offer a promising approach for assuring efficacy while potentially mitigating toxicity. Optimization of antibody binding properties may enable the development of safer and more effective TROP2-targeted therapeutics.
    Journal
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    7d
    Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, National Cancer Centre, Singapore
    New P2 trial
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Jiataile (sacituzumab tirumotecan)
    10d
    First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study. (PubMed, Clin Cancer Res)
    SG plus pembrolizumab and carboplatin had activity in mNSCLC. When combined with pembrolizumab and carboplatin, SG was tolerated at a dose of 7.5 mg/kg.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • Trodelvy (sacituzumab govitecan-hziy)